BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 15, 2026
Breaking News: New research identifies EBV antigen targets for MS therapiesBreaking News: New research identifies EBV antigen targets for MS therapiesBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

Neurology/psychiatric

Sironax identifies SARM1 modulators for axonal degeneration

July 11, 2024
Sironax Ltd. has discovered (+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, diabetic neuropathy, multiple sclerosis, Parkinson's disease, chemotherapy-induced peripheral neuropathy and traumatic brain injury.
Read More
Neurology/psychiatric

XYY-CP1106 for Alzheimer’s demonstrates promising preclinical safety profile

July 11, 2024
Zhejiang University of Technology has reported preclinical safety data for the novel multitargeting compound XYY-CP1106, being developed for the treatment of Alzheimer’s disease (AD). XYY-CP1106 is a multitargeted anti-AD compound that has previously demonstrated strong monoamine oxidase B (MAO-B) inhibition (IC50=14.7 nM), high Fe3+ chelation (pFe3+=18.04), no in vitro cytotoxicity and protection against cellular oxidative damage.
Read More
Illustration demonstrating parts of the ear
Drug design, drug delivery & technologies

A gene therapy could restore hearing in adults

July 11, 2024
By Mar de Miguel
Patients with congenital hearing loss could benefit from a gene therapy currently in development. Although there are approaches that could reverse the process in children and young people before it becomes severe, so far, adults do not have any treatment that prevents the progressive deterioration of auditory sensory cells caused by this disease.
Read More
Neurology/psychiatric

Daiichi Sankyo reports orexin OX2 receptor agonists for narcolepsy

July 10, 2024
Daiichi Sankyo Co. Ltd. has prepared and tested new 2-azabicyclo[3.1.1]heptane compounds acting as orexin OX2 receptor agonists with potential for the treatment of narcolepsy.
Read More
Neurology/psychiatric

Karuna Therapeutics patents muscarinic M4 receptor agonists

July 10, 2024
Work at Karuna Therapeutics Inc. has led to the identification of substituted tetrahydropyrrolo-pyridinone compounds acting as muscarinic M4 receptor agonists and/or positive allosteric modulators.
Read More
Brain and DNA
Neurology/psychiatric

GA-VAX-01 shows promising results for C9orf72-associated ALS and FTD

July 10, 2024
Many patients with amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD) harbor the (G4C2)n pathogenic repeat expansion in the C9orf72 gene, which leads to aggregating dipeptide proteins, mainly poly-glycine-alanine (poly-GA).
Read More
Multiple sclerosis, neurons concept art.
Neurology/psychiatric

Abata obtains IND clearance for autologous TCR-Treg therapy for progressive MS

July 10, 2024
Abata Therapeutics Inc. has obtained FDA clearance for its IND application enabling initiation of a first-in-human study of ABA-101 in patients with progressive multiple sclerosis (MS). A phase I study will open later this year.
Read More
Illustration highlighting the brain's reward circuit.
Substance use & poisoning

Suvorexant prevents opioid-induced brain changes

July 10, 2024
Brains from people with heroin use disorder have an increased number of hypocretin (Hcrt, orexin) neurons, which in turn are significantly smaller than in healthy controls. Meanwhile, human narcolepsy is known to present an average 90% loss of Hcrt neurons and no risk for drug abuse or overdose, even under methamphetamine or methylphenidate prescription, because of a greatly reduced reward activation of the ventral tegmental area (VTA).
Read More
Neurology/psychiatric

Celgene discovers new S1P5 receptor modulators

July 9, 2024
Celgene Corp. has patented sphingosine 1-phosphate S1P5 receptor (EDG8) modulators reported to be useful for the treatment of Alzheimer’s disease and multiple sclerosis.
Read More
Neurology/psychiatric

Grünenthal identifies new Nav1.8 blockers for pain

July 9, 2024
Several Grünenthal GmbH patents describe sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers potentially useful for the treatment of pain.
Read More
Previous 1 2 … 119 120 121 122 123 124 125 126 127 … 2813 2814 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 14, 2026.
  • AI-generated  illustration of a neuron with tau protein aggregation

    AAIC 2026: Age of amyloid is being joined by time of tau

    BioWorld
    The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 14, 2026
  • Senior medical exam

    Celia trial: data strong, analysts skeptical

    BioWorld
    Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing